Davis Investment Partners LLC Takes $553,000 Position in IQVIA Holdings Inc. $IQV

Davis Investment Partners LLC bought a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 3,240 shares of the medical research company’s stock, valued at approximately $553,000.

Other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC grew its holdings in shares of IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after purchasing an additional 2,537 shares in the last quarter. Empowered Funds LLC raised its stake in shares of IQVIA by 102.1% in the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock valued at $1,715,000 after purchasing an additional 4,915 shares in the last quarter. Sivia Capital Partners LLC bought a new position in IQVIA in the second quarter worth $514,000. First Trust Advisors LP lifted its position in IQVIA by 14.8% in the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock worth $14,501,000 after purchasing an additional 11,845 shares during the period. Finally, NewEdge Advisors LLC boosted its stake in IQVIA by 5.4% during the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock worth $3,582,000 after buying an additional 1,155 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on IQV. HSBC set a $210.00 price objective on shares of IQVIA in a research note on Wednesday, June 3rd. Barclays raised shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price target for the company in a research report on Friday, March 6th. Weiss Ratings cut shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Morgan Stanley reaffirmed an “equal weight” rating and set a $200.00 price objective (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. Finally, Royal Bank Of Canada started coverage on IQVIA in a research note on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $222.56.

IQVIA Trading Up 8.5%

IQV stock opened at $185.76 on Thursday. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $247.04. The company has a market cap of $31.00 billion, a P/E ratio of 23.02, a PEG ratio of 1.47 and a beta of 1.21. The business has a fifty day moving average of $173.95 and a 200-day moving average of $190.34.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.83 by $0.07. The business had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter last year, the business earned $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 11.6 EPS for the current year.

IQVIA announced that its Board of Directors has approved a stock repurchase plan on Thursday, May 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s board believes its stock is undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.